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ABSTRACT  
Objective: The objective of this research was to formulate and evaluate pectin and HPMC different grades mucoadhesive microspheres in 
combination with sodium alginate for controlled release of maraviroc. 
Methods: The maraviroc mucoadhesive microspheres was successfully developed by Ionotropic gelation technique, using sodium alginate, pectin, 
HPMC K4, K15, and K100 as mucoadhesive polymer in various proportions in combination. Further, the prepared maraviroc mucoadhesive 
microspheres were characterized for particle size, morphology, micrometric studies, entrapment efficiency, mucoadhesion, in vitro drug release, 
release kinetics, compatibility studies (FTIR) and stability studies. 
Results: The maraviroc Microspheres was discrete and free-flowing. The mean particle size ranged from 646.3±10.2 μm to 910.0±6.56 μm and the 
entrapment efficiency ranged from 50.80% to 91.43%. Entrapment efficiency of maraviroc microspheres was increased by increasing drug to 
mucoadhesive polymer ratio. Scanning electron microscopy revealed the rough surface morphology and no visible cracks of best formulation F16. The 
FTIR study confirmed the stable nature of maraviroc in the drug-loaded mucoadhesive microspheres. All the maraviroc microspheres showed good 
mucoadhesive property ranging from 04-73 % in the in-vitro wash off test after 8 hours. The Crystallinity of maraviroc was found to be reduced in 
prepared mucoadhesive microspheres, which were confirmed by XRD studies. The mechanism of maraviroc release from the mucoadhesive 
microsphere was found to be anomalous and super case-II transport type. Stability studies were carried out for the best formulation F16 indicates that 
there is no change in entrapment efficiency and percentage mucoadhesion of the formulation. 
Conclusion: The results obtained in this research work clearly indicated a promising potential of control release maraviroc mucoadhesive 
microspheres containing HPMC K100 as a rate controlling polymer for the effective treatment of AIDS/HIV patients. 
Keywords: Pectin, HPMC K4, HPMC K15M, HPMC K100, Maraviroc, Mucoadhesive microspheres. 
 
INTRODUCTION  
Oral controlled drug delivery systems continue to be the most 
accepted and popular one among all the drug delivery systems as it 
offers several advantages over the conventional drug delivery 
systems like; Improving patient’s compliance and convenience due 
to reduction of frequency of administration [1]. The problem 
commonly encountered with the controlled release delivery system 
is the inability to restrain and localize the dosage form at the 
gastrointestinal tract, due to the rapid gastrointestinal transit 
phenomenon [2]. In order to overcome this limitation, it has been 
proposed, to coupling the bioactives to microparticulate systems an 
important part of novel drug delivery [3]. However, the success of 
microparticulate carrier system is limited due to their limited 
residence time at the site of absorption [4]. It can be executed by 
coupling mucoadhesion characteristics to microparticulate by using 
mucoadhesive polymers and developing mucoadhesive 
microspheres [5]. Mucoadhesive microspheres have advantages like 
efficient absorption and improved bioavailability of the bioactives 
due to high surface to volume ratio, an intimate contact with the 
mucus membrane and drug targeting to the absorption site [6]. 
Maraviroc is a new class of anti HIV drug known as CCR5 antagonists
 and only oral entry inhibitor approved for the treatment of HIV 1inf
ection [7]. Maraviroc poorly absorbed from lower gastrointestinal 
tract and the oral bioavailability after a single 300-mg oral dose is 
reported to be 33% with biological half life of 10.6±2.7 h. 
Administration of conventional dosage form suffers from certain 
drawbacks like first pass metabolism, variation of absorption and 
fluctuation in the plasma drug level [8].  
In our previous investigation [9], sodium alginate mucoadhesive 
microspheres of maraviroc controlled the drug release for 8 hrs. To 
prolong the maraviroc release, improve mucoadhesion, 
bioavailability and to reduce dosing frequency, a suitable 
formulation was required with a controlled rate to treat anti HIV 
patients. In the present study, mucoadhesive microspheres were 
developed using a hydrophilic polymer, Hydroxypropyl 
methylcellulose (HPMC K4M, K15M and K100) and pectin in 
combination with sodium alginate.  
MATERIALS AND METHODS  
Materials 
Maraviroc was a gift sample from Hetro Pharma Ltd, Hyderabad. 
Sodium alginate, HPMC different grades, pectin polymers were 
received as the gift sample from Cadila Pharma, Ahmedabad, India. 
All other ingredients used were of analytical grade. 
Formulation of Maraviroc mucoadhesive microspheres 
The Maraviroc mucoadhesive microspheres were prepared by 
Ionotropic external gelation technique [10, 11], the composition of 
various formulations was mentioned in Table1. Maraviroc and 
mucoadhesive polymers were individually passed through sieve number 
60. The required quantities of mucoadhesive polymers were dissolved in 
purified water to form a homogenous polymer solution. Maraviroc was 
added to the polymer solution and mixed thoroughly with stirrer at 400 
rpm to form a homogeneous dispersion. The resulting homogeneous 
dispersion was sonicated for 30 min to remove any air bubbles. For the 
formation of microspheres the dispersion was then extruded manually 
drop wise into aluminum sulphate solution (10%) using a 
polyethylene syringe (needle size 24 G). The extruded droplets were 
retained in the aluminium sulphate solution for 30 min to complete 
the curing reaction and to produce spherical rigid maraviroc 
microspheres [9]. The obtained microspheres were collected by 
decantation, washed repeatedly with distilled water to remove excess 
aluminum impurity and dried at 45 °C for12 h. 
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Table 1: Composition of Maraviroc mucoadhesive microspheres 
Formulation code Drug: polymer ratio Polymer ratio 
F1 1:0.5 0.25:0.25 (Sodium alginate: Pectin) 
F2 1:1 0.5:0.5 (Sodium alginate: Pectin) 
F3 1:1.5 0.75:0.75 (Sodium alginate: Pectin) 
F4 1:2 1:1 (Sodium alginate: Pectin) 
F5 1:0.5 0.25:0.25 (Sodium alginate: HPMC K4) 
F6 1:1 0.5:0.5 (Sodium alginate: HPMC K4) 
F7 1:1.5 0.75:0.75 (Sodium alginate: HPMC K4) 
F8 1:2 1:1 (Sodium alginate: HPMC K4) 
F9 1:0.5 0.25:0.25 (Sodium alginate: HPMC K15) 
F10 1:1 0.5:0.5 (Sodium alginate: HPMC K15) 
F11 1:1.5 0.75:0.75 (Sodium alginate: HPMC K15) 
F12 1:2 1:1 (Sodium alginate: HPMC K15) 
F13 1:0.5 0.25:0.25 (Sodium alginate: HPMC K100) 
F14 1:1 0.5:0.5 (Sodium alginate: HPMC K100) 
F15 1:1.5 0.75:0.75 (Sodium alginate: HPMC K100) 
F16 1:2 1:1 (Sodium alginate: HPMC K100) 
 
Percentage yield 
The percentage yield of Mucoadhesive microsphere of various 
batches was calculated by using the weight of the final product after 
drying. The weight of dried maraviroc microspheres (W1) was 
divided by initial total weight of the drug and polymers (W2).  
Micromeritic properties of Maraviroc microspheres 
The flow properties of prepared maraviroc mucoadhesive 
microsphere were studied by determining various parameters like 
the tapped density, bulk density, Carr’s index, Hausner’s ratio and 
angle of repose. 
Particle size 
Particle size and size distribution of the maraviroc microspheres 
was measured by sieve analysis method [12]. The maraviroc 
microspheres were separated into different size fractions (% mass 
fraction) by sieving for 5 min using standard sieves having a nominal 
mesh opening of 1.0 mm, 0.85 mm, 0.71 mm, 0.60 mm and 0.50 mm 
and the mean particle size of the maraviroc microspheres was 
determined. 
Morphology of microspheres 
The surface morphology and shape of the Maraviroc microspheres 
were confirmed by scanning electron microscopy using the SEM 
Model (JSM 6390 India). The sample was mounted onto an 
aluminum stub and sputter-coated with platinum particles in an 
argon atmosphere [13].  
Drug entrapment efficiency 
Entrapment efficiency of prepared maraviroc microsphere was 
estimated by the method of extraction of the drug present in 
microsphere. The dried mucoadhesive microspheres (100 mg) were 
taken and extracted with 100 ml of 0.1N HCl for 24 h in the rotary 
shaker. The solution was filtered through a 0.45 μm filter and the 
concentration of maraviroc present in filtrate determined Spectro 
photometrically at 210 nm (LABINDIA UV-3092 PC) against 0.1 N 
HCl as a blank [14]. 
Mucoadhesive test 
The mucoadhesive property of Maraviroc microspheres was 
evaluated by in vitro wash off test. The freshly excised piece of the 
goat intestinal mucosa was mounted on the glass slide using 
cyanoacrylate glue. About 100 microspheres were spread onto each 
wet rinsed tissue specimen and immediately thereafter the support 
was hang onto the arm of the USP disintegration machine. Now 
operating the disintegration test apparatus, the intestinal mucosa 
was given a slow, regular up and down movement in the test fluid 
(0.1N HCL buffer) at 37±0.5 °C. At predetermined time intervals up 
to 8 h the equipment was stopped and the number of Maraviroc 
mucoadhesive microspheres still sticking onto the intestinal mucosa 
was counted and percent mucoadhesion was calculated [15].  
In vitro dissolution 
The in vitro dissolution studies of prepared Maraviroc microspheres 
were carried out using USP type II (paddle) dissolution test 
apparatus. Microspheres containing equivalent to 100 mg of 
Maraviroc were introduced into 900 ml dissolution medium of 0.1N 
HCl for 12 hrs at 37±0.5 °C at a rotation speed of 50 rpm. 5 ml of the 
aliquots was withdrawn through a filter (0.45 μ) at the regular 
interval of every 1h and replaced with an equal volume of fresh 0.1N 
HCl buffer. The samples were analyzed at 210 nm for maraviroc 
content using a UV spectrophotometer. The maraviroc release 
experiments were carried out in three replicate [16].  
Release kinetics and mechanism of maraviroc release 
The rate and the mechanism of release of maraviroc from the 
prepared mucoadhesive microspheres were analyzed by fitting the 
dissolution data into various kinetic models like zero order; first 
order, korsemeyer peppas, Higuchi’s model and Coefficient of 
determination r2 values were calculated for the liner curves by 
regression analysis of the above plots [17]. 
FTIR studies  
Compatibility study of Maraviroc with different mucoadhesive 
polymers was determined by Fourier transform infrared 
Spectroscopy (FTIR) using Shimadzu FT-IR spectrometer model. IR 
spectra for maraviroc and powdered maraviroc microspheres were 
recorded in an FTIR spectrophotometer with KBr pellets the 
scanning was done between wave numbers 4000 to 400 cm-1at 4 cm-
1resolution [18, 19]. 
X-ray diffraction study (XRD) 
The crystallinities of Maraviroc and Maraviroc loaded mucoadhesive 
microspheres were evaluated by XRD measurement using an X-
ray diffractometer. XRD studies were performed on the prepared 
samples by exposing them to Cuk α1 radiation (40 KV, 30 MA) and 
the scanning rate was 5 °/min over a range of 4-90 ° and with an 
interval of 0.1 [20].  
Stability study  
Stability studies were carried out for maraviroc formulation as per 
ICH guidelines. The best mucoadhesive microspheres formulation 
(F16) was sealed in high density polyethylene bottles and stored at 
4±1 °C/Ambient, 25±2 °C/60±5 % RH %, 40±2 °C/75±5 % RH for 
90days. The samples were periodically evaluated for entrapment 
efficiency and percentage mucoadhesion [21, 22].  
RESULTS AND DISCUSSION 
Percentage yield and micromeritics studies 
The prepared maraviroc microsphere by ionotropic gelation method 
was found to be spherical shape and free flowing in nature. The 
production yields of maraviroc microspheres formulations were 
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found to be between 82 to 95% as shown in table 2. The prepared 
batches of maraviroc microspheres were evaluated for micromeritic 
study such as, bulk density, tapped density, Compressibility index, 
Hausner’s ratio and angle of repose (table 3). The bulk density of the 
formulations ranged from 0.305-0.525g/ml. The tapped density of 
the different formulations ranged from 0.362-0.578 
g/ml. Compressibility index values of the different batches of 
maraviroc microspheres ranged from 09.033 % to 15.58 %. 
Hausner’s ratio varied from 1.10 to 1.185. The angle of repose of all 
the formulations ranged from19.67 to 32.37°. Based on the above 
micromeritic properties all the batches of maraviroc mucoadhesive 
microspheres revealed excellent flow and packaging properties. 
 




yield a  
Theoretical drug content 
(mg) 




 Particle size 
[μm] a 
F1 90.96±3.56 66.60 33.84±0.14 50.81±0.22  652.02±5.35 
F2 91.93±2.79 50.00 27.97±0.06 55.95±0.12 676.29±2.31 
F3 94.56±2.31 40.00 25.44±0.08 63.60±0.20 711.88±2.25 
F4 97.83±2.01 33.00 22.99±0.08 69.66±0.25 748.75±3.13 
F5 86.50±3.87 66.60 42.80±1.20 64.26±1.80 712.29±4.77 
F6 89.43±3.02 50.00 35.92±0.91 71.84±1.81 737.92±1.57 
F7 93.11±2.61 40.00 31.75±0.02 79.37±0.06 764.38±3.13 
F8 95.15±2.09 33.00 27.91±0.09 84.57±0.28 809.73±2.61 
F9 89.40±3.73 66.60 46.13±1.01 69.27±1.51 758.13±3.13 
F10 93.33±3.07 50.00 38.19±0.53 76.37±1.06 790.39±2.93 
F11 94.18±2.64 40.00 33.83±0.02 84.57±0.06 827.13±3.63 
F12 95.91±2.39 33.00 29.45±0.16 89.25±0.49 858.54±5.54 
F13 91.64±3.93 66.60 48.93±0.61 73.47±0.92 790.39±2.93 
F14 93.92±3.20 50.00 41.07±0.61 82.13±1.22 824.71±5.54 
F15 92.51±2.75 40.00 35.43±0.06 88.57±0.15 870.63±3.63 
F16 93.63±2.69 33.00 30.17±0.06 91.43±0.19 910.50±7.25 
amean±SD, n = 3. 
 
Table 3: Micromeritic properties of Maraviroc mucoadhesive microspheres 
Formulation code Bulk density a Tapped density a Compressibility index a Hausner’s ratio a Angle of repose a 
F1 0.525±0.020 0.578±0.037 9.033±2.57 1.100±0.032 19.67±0.649 
F2 0.484±0.013 0.547±0.025 11.43±1.81 1.129±0.023 21.00±0.390 
F3 0.455±0.010 0.518±0.017 12.19±1.33 1.139±0.017 22.72±0.415 
F4 0.432±0.011 0.500±0.018 13.73±1.04 1.176±0.014 23.21±0.742 
F5 0.464±0.018 0.527±0.033 11.96±2.48 1.136±0.033 20.10±0.386 
F6 0.426±0.012 0.488±0.021 12.72±1.66 1.146±0.022 24.10±0.613 
F7 0.408±0.013 0.479±0.022 14.63±1.25 1.191±0.017 26.58±0.882 
F8 0.397±0.010 0.463±0.016 14.36±0.99 1.168±0.014 28.62±0.547 
F9 0.399±0.020 0.453±0.024 11.90±0.55 1.135±0.007 25.09±0.468 
F10 0.373±0.014 0.428±0.022 12.68±1.39 1.145±0.018 26.25±0.271 
F11 0.357±0.012 0.409±0.018 12.64±1.05 1.145±0.014 28.79±0.596 
F12 0.343±0.010 0.396±0.015 13.50±0.83 1.156±0.011 30.28±1.040 
F13 0.362±0.013 0.409±0.02 11.43±1.81 1.129±0.023 24.64±0.905 
F14 0.348±0.012 0.394±0.018 11.74±1.27 1.133±0.016 26.10±0.462 
F15 0.330±0.011 0.375±0.016 11.91±0.98 1.135±0.013 28.93±0.547 
F16 0.305±0.010 0.362±0.015 15.58±0.78 1.185±0.011 32.37±0.639 
amean±SD, n = 3. 
  
 
Fig. 1: Scanning electron photomicrographs of the Formulation F16, A): 80 X, B): 500 X, C): 7000X, D): 3000X 
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Particle size  
The mean particle size of maraviroc mucoadhesive microspheres 
ranged from 646.3±10.2 to 910.0±6.56 μm. The results revealed that 
the mean particle size increase with increases in mucoadhesive 
polymer concentration. It would appear that increasing 
mucoadhesive polymer concentration produced a significant 
increase in viscosity of the dispersion, thus leading to an increase of 
droplet size and finally a higher microsphere size [23]. 
Morphology of microspheres 
The SEM photographs revealed that obtained maraviroc 
microspheres were discrete and spherical shape with a rough 
surface morphology (fig.1) which could be due to the surface 
association of the Maraviroc with mucoadhesive polymer [24]. 
Entrapment efficiency 
Maraviroc microspheres were characterized for percentage 
entrapment efficiency. The percentage entrapment efficiency ranged 
from 50.80 to 91.43%. (table 2). The entrapment efficiency of the 
microspheres prepared with HPMC K100 was higher than those of 
microspheres prepared with HPMC K4, K15 and pectin. From the 
result, it was observed that increase in the molecular weight of the 
mucoadhesive polymer increase the entrapment efficacy. This can 
be due to increase in the viscosity of the polymeric solution, which 
increases, the greater availability of aluminium binding sites in 
polymeric chains. As a result formation of the more intact matrix 
network, entrapping a higher amount of the maraviroc drug [25]. 
Mucoadhesive test 
The results of the in-vitro mucoadhesion studies of all the 
formulations were shown in table 4. Percentage mucoadhesion of 
formulations increased with the increase in concentration of 
mucoadhesive polymers. The higher mucoadhesion of HPMC K100 
based mucoadhesive microspheres may be attributed to higher 
molecular weight of HPMC K100 than HPMC K4, K15 and Pectin based 
microspheres. The in vitro wash-off was faster at simulated intestinal 
fluid (pH 7.4) than that at simulated gastric fluid (pH 1.2). Our result is 
supported by the report of Robinson et al. [26]. The solubility, 
hydration and mucoadhesiveness of the polymers depend on the pH of 
the in-vitro wash off medium. The rapid in-vitro wash-off observed at 
simulated intestinal fluid may be due to the ionization of the carboxyl 
acid group and other functional groups in the mucoadhesive polymers, 
which increase their solubility and reduce mucoadhesive strength. The 
results of the in-vitro wash-off test indicated that the maraviroc 
microspheres had fairly good mucoadhesive properties. The 
developed maraviroc mucoadhesive microspheres would adhere to 
the Gastro intestinal walls, thus resisting gastric emptying and prolong 
the residence time at the absorption site, thereby improve and 
enhance the bioavailability [27, 28]. 
 
Table 4: Results of in vitro wash off test 
Hours In 0.1 M HCL (pH 1.2) a In phosphate buffer (pH 7.4) a 
1 2 4 6 8 1 2 4 6 8 
F1 83±1.53 46±3.06 19±3.21 03±2.31 - 80±1.53 41±0.58 15±2.52 - - 
F2 90±3.06 62±2.65 39±2.52 17±2.52 - 85±1.53 57±1.73 33±2.52 13±2.48 - 
F3 95±3.00 74±3.06 51±3.61 30±3.00 10±3.21 89±1.17 71±2.08 44±0.58 22±1.00 5±1.15 
F4 97±0.58 78±2.52 57±2.00 36±2.08 20±3.06 93±1.53 74±1.73 54±1.15 31±2.31 14±1.73 
F5 98±1.15 90±0.58 64±2.52 37±1.15 04±1.53 96±1.00 85±0.58 57±2.08 33±2.31 - 
F6 100 93±1.15 71±1.73 41±1.15 16±1.53 97±0.58 89±1.15 67±1.53 38±1.73 13±1.00 
F7 100 98±1.53 73±1.53 50±1.15 28±2.08 98±1.15 92±1.53 70±1.00 46±1.73 23±1.15 
F8 100 100±0.58 77±1.53 61±1.53 41±2.08 99±0.58 96±1.53 72±2.52 58±1.15 36±1.73 
F9 100 92±1.53 76±1.15 52±1.73 31±0.58 98±1.15 88±0.58 71±1.53 48±1.73 27±0.58 
F10 100 98±1.15 85±2.52 70±1.73 46±3.06 99±0.58 92±2.52 81±1.73 67±2.08 42±2.65 
F11 100 98±0.58 85±2.08 72±1.53 57±1.53 100 94±1.53 82±1.73 69±1.53 53±2.08 
F12 100 100 89±1.53 77±2.08 65±0.58 100 96±1.00 85±0.58 73±1.53 61±0.58 
F13 100 98±1.53 84±2.52 68±1.15 47±1.53 98±0.58 93±1.15 81±2.31 62±1.53 43±2.00 
F14 100 99±1.00 86±1.15 71±1.15 56±2.08 99±0.58 95±1.53 83±2.31 67±1.73 52±2.08 
F15 100 99±1.15 88±2.08 74±2.00 62±1.00 100 97±1.53 85±1.53 71±2.31 56±1.15 
F16 100 100 92±1.15 81±1.15 73±0.58 100 99±0.58 89±1.73 79±2.31 68±1.73 
amean±SD, n = 3. 
 
 
Fig. 2: Comparative in vitro drug release profile of formulation 
F1 to F8 
 
Fig. 3: Comparative in vitro drug release profile of formulation 
F9 to F16 
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In vitro dissolution studies 
The in vitro Maraviroc release profiles for all batches was shown in fig. 
2-3. The Maraviroc release behaviors depend upon the type and 
amount of mucoadhesive polymers in polymer matrix [29, 30]. Pectin-
alginate microspheres (F1 and F4) were able to control the maraviroc 
release up to 8 h, whereas HPMC different grades microspheres were 
able to control the drug released up to 12 h. It has been observed that 
Pectin, HPMC K4, HPMC K15 based mucoadhesive  micro 
spheres showed the comparatively rapid drug release as compared to 
HPMC K100 based formulations. It was found that there was decrease 
in drug release with increase in mucoadhesive polymer content. This 
could be attributed to the greater degree of swelling upon hydration 
with greater mucoadhesive polymer content in the microspheres 
which leads to increase in the diffusional path length that slows down 
drug release. The prolong drug release of maraviroc microspheres was 
shown by F16 formulation (88.71) in 12 hours and hence it is 
considered as the best formulation which seems to be a good 
candidate for controlled release. 
Release kinetics and mechanism of maraviroc release 
Drug release kinetic data for maraviroc microspheres were shown in 
table 5. All the formulations (F1 to F16) follow zero order release 
kinetics with regression values ranging from 0.894 to 0.984. 
Korsmeyer-Peppas plots, ‘n’ value ranges from 0.622 to 1.425 
indicating that the maraviroc release mechanism followed the 
anomalous transport and super case-II transport mechanism. 
  
Table 5: Release kinetic parameter of maraviroc from mucoadhesive microspheres 
Formulation code Zero order First order Higuchi Korsmeyer peppas n-value Hixson crowel 
F1 0.894 0.840 0.917 0.952 0.622 0.851 
F2 0.922 0.903 0.951 0.959 0.773 0.801 
F3 0.951 0.880 0.964 0.968 0.878 0.761 
F4 0.971 0.871 0.967 0.967 0.967 0.685 
F5 0.937 0.838 0.957 0.971 0.811 0.634 
F6 0.966 0.750 0.95 0.958 0.947 0.547 
F7 0.984 0.800 0.951 0.97 1.021 0.577 
F8 0.983 0.763 0.929 0.96 1.094 0.473 
F9 0.964 0.686 0.961 0.976 0.907 0.533 
F10 0.984 0.637 0.956 0.971 1.033 0.452 
F11 0.984 0.572 0.93 0.961 1.147 0.352 
F12 0.971 0.817 0.901 0.978 1.278 0.763 
F13 0.983 0.636 0.953 0.971 1.024 0.452 
F14 0.982 0.766 0.928 0.964 1.159 0.472 
F15 0.972 0.794 0.903 0.98 1.33 0.717 
F16 0.959 0.828 0.881 0.982 1.425 0.789 
 
FTIR studies 
The infrared spectrum of pure maraviroc showed a broad 
absorption band at 2934 cm-1, assigned to the stretching vibration 
of the amide N-H group, a sharp band at 1663 cm-1 assigned to 
stretching vibrations of the carbonyl group, the 1530 cm-1band is 
due to the bending vibration of amide N-H group and a sharp band 
at 703 assigned to phenyl group. Overall, the results of spectrum 
analysis indicated that Maraviroc loaded Microspheres showed the 
characteristic peaks of the pure drug at 2934 cm-1 indicating that 
there was no interaction between the Maraviroc and 
mucoadhesive polymers. 
X-ray Diffraction study (XRD) 
The X-ray diffractograms of Maraviroc and formulation F16 are 
shown in fig. 5. Pure Maraviroc has shown characteristic intense 
peaks due to its crystalline nature. Whereas, in case of formulation 
F16 showed a less intense peak of low intensity, revealing 
amorphous dispersion of the drug after entrapment into 
mucoadhesive microspheres [31]. 
 
 
Fig. 4: FTIR spectra of, (A): Pure Maraviroc; (B): Formulation containing Pectin; (C): Formulation containing HPMC K4; (D): Formulation 
containing HPMC K15; (E): Formulation containing HPMC K100 (F16) 
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Fig. 5: XRD pattern of, (A): Pure Maraviroc; and (B): Best formulation F16 
 
Table 6: Percentage entrapment efficiency and mucoadhesion of the F16 formulation 
Stability condition Sampling day Percentage 





4 °C/Ambient 30 91.43±0.19  72.67±0.58 
60 91.07±0.07  70.33±1.15 
90 90.67±0.12  69.67±1.53 
25 °C/60 RH 30 91.23±0.19  73.67±1.15 
60 91.15±0.12  70.00±1.73 
90 91.07±0.28  68.67±1.53 







amean±SD, n = 3. 
 
Stability study  
After 3 months, storage of F16 formulation at 4±1 °C/Ambient, 25±2 
°C/60±5 % RH, 40±2 °C/75±5 % RH, percentage entrapment 
efficiency, percentage mucoadhesion were checked and found to be 
almost similar to the initial values. There was no substantial 
alteration in any value and also the physical appearance. So it can be 
said that maraviroc mucoadhesive microspheres prepared with 
HPMC K100 is stable. 
CONCLUSION  
The HPMC K100 mucoadhesive microspheres containing maraviroc 
can be successfully prepared by ionotropic gelation technique. The 
prepared Maraviroc mucoadhesive microspheres were spherical and 
free flowing. The entrapment efficiencies ranged from 50.80 to 
91.43% and mean size was in the range of 646.3±10.2 μm to 
910.0±6.56 μm. Concentration of mucoadhesive polymer ratio 
influences the entrapment efficiency and maraviroc release profile 
of microspheres. Thus the investigation clearly indicated a 
promising potential of control release maraviroc mucoadhesive 
microspheres containing HPMC K100 as rate controlling polymer for 
the effective treatment of AIDS/HIV patients. 
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